Nichola Davies - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Nichola Davies's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Nichola Davies
Verified
Digital Journalist, Local Government Association of Queensland
Brisbane
Beats
city and environmental news related to melbournelifestyle
Content
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
By Clare Thomson, Erin Braybrooke, Nicola Colclough, Nichola Davies Verified| ACS Publications@ IntroductionClick to copy section linkSection link copied!A diverse range of therapies for the treatment of EGFR mutated non-small cell lung cancer (NSCLC) have been developed over many years, primarily to treat patients with common activating mutations including Exon 19 deletions and L858R single point mutations, which jointly account for 90% of all activation mutations.
By Nichola Davies Verified| The Analytical Scientist Verified Graham: The challenge of data heterogeneity is real (1) – and it was highlighted in the survey from ACD/Labs and The Analytical Scientist’s on analytical data management (see the infographic below for the headline figures). Labs are often dealing with a variety of different vendor technologies, software, and hardware all collecting data, which makes summarizing the information difficult.
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
By Clare Thomson, Erin Braybrooke, Nicola Colclough, Nichola Davies Verified| ACS Publications@ IntroductionClick to copy section linkSection link copied!A diverse range of therapies for the treatment of EGFR mutated non-small cell lung cancer (NSCLC) have been developed over many years, primarily to treat patients with common activating mutations including Exon 19 deletions and L858R single point mutations, which jointly account for 90% of all activation mutations.